Last reviewed · How we verify

azithromycin and cefixime

Sheba Medical Center · FDA-approved active Small molecule

This combination uses azithromycin (a macrolide antibiotic) and cefixime (a third-generation cephalosporin) to inhibit bacterial protein synthesis and cell wall synthesis, respectively, providing broad-spectrum coverage against multiple pathogens.

This combination uses azithromycin (a macrolide antibiotic) and cefixime (a third-generation cephalosporin) to inhibit bacterial protein synthesis and cell wall synthesis, respectively, providing broad-spectrum coverage against multiple pathogens. Used for Respiratory tract infections (community-acquired pneumonia, bronchitis), Urogenital infections (gonorrhea, chlamydia), Mixed bacterial infections.

At a glance

Generic nameazithromycin and cefixime
SponsorSheba Medical Center
Drug classCombination antibiotic (macrolide + third-generation cephalosporin)
TargetBacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Azithromycin binds to the bacterial 50S ribosomal subunit to inhibit protein synthesis, while cefixime inhibits bacterial cell wall cross-linking by binding to penicillin-binding proteins. Together, they provide synergistic activity against a wide range of gram-positive and gram-negative bacteria, commonly used for respiratory and urogenital infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: